Note that in one AML mice model, the combination of PI3K and DNA-PK inhibitors prolonged survival of treated mice [76]; one can suggest that MRE11 should represent an alluring alternative or additional target. This evidence concerns the gene MRE11 and acute myeloid leukemia.